Mazindol treatment of negative symptoms

William T. Carpenter, Alan Breier, Robert W. Buchanan, Brian Kirkpatrick, Paul Shepard, Elaine Weiner

Research output: Contribution to journalArticle

13 Scopus citations


Hypodopaminergic and hyponoradrenergic pathophysiology may be a basis for primary and/or secondary negative symptoms in schizophrenia. The hypothesis that enhanced neurotransmission in these systems would be therapeutic for negative symptoms was tested by comparing mazindol and placebo in a double-blind, cross-over design trial. Outcome following mazindol supplementation was comparable to placebo supplementation (F(1,30) = 0.9; p = .57). Results for deficit and non-deficit schizophrenia subjects were similar, and were not affected by whether concurrent the antipsychotic drug treatment was clozapine, fluphenazine, or haloperidol. The efficacy hypothesis was not supported for either primary or secondary negative symptoms. (C) 2000 American College of Neuropsychopharmacology.

Original languageEnglish (US)
Pages (from-to)365-374
Number of pages10
Issue number4
StatePublished - Oct 1 2000
Externally publishedYes


  • Clinical trial
  • Dopamine
  • Mazindol
  • Negative symptoms
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Mazindol treatment of negative symptoms'. Together they form a unique fingerprint.

  • Cite this

    Carpenter, W. T., Breier, A., Buchanan, R. W., Kirkpatrick, B., Shepard, P., & Weiner, E. (2000). Mazindol treatment of negative symptoms. Neuropsychopharmacology, 23(4), 365-374.